A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the ...
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...
Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...
The company wants to create two focused companies dedicated to driving current and future value in their respective ...
Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while ...
The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported ...
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
Vivani Medical (VANI) announced that it intends to spin off Cortigent, a division that develops brain implant devices to help people recover ...
Rapid full study enrollment with all 24 subjects initiating the 8-week run-in period within four weeks; top-line study results expected in mid-2025 Vivani Medical, Inc. (NASDAQ: VANI ...
Our mission at Vivani remains unchanged as we continue to leverage our proprietary NanoPortalâ„¢ implant technology and advance the development of our portfolio of miniature, subdermal GLP-1 ...
Vivani also expects the results to support the potential application of a GLP-1 (exenatide) implant for type 2 diabetes and other diseases. Find out which stock just plummeted to the bottom of the ...